# Developing and optimizing a biocompatible tauopathy model using extracellular vesicle-mediated gene delivery

**Authors:** Samaneh Ghadami, Kristen Dellinger

PMC · DOI: 10.3389/fmed.2025.1672046 · Frontiers in Medicine · 2025-10-22

## TL;DR

This study shows that extracellular vesicles can efficiently and safely deliver genes to create models for studying tau-related diseases like Alzheimer's.

## Contribution

The paper introduces an optimized, biocompatible method for gene delivery using extracellular vesicles for tauopathy modeling.

## Key findings

- EVs successfully delivered large plasmid DNA into Neuro-2a cells, resulting in detectable tau and EGFP expression.
- Optimization via RSM improved EV-mediated gene delivery efficiency and reproducibility over conventional methods.
- EVs offer a biocompatible and effective alternative to traditional transfection strategies for tauopathy models.

## Abstract

Tauopathy models are essential in vitro systems for investigating tau-targeted therapies and advancing Alzheimer’s disease research. Extracellular vesicles (EVs), owing to their high biocompatibility, low toxicity, and reduced immunogenicity, represent promising carriers for gene delivery and disease modeling.

We investigated the potential of EVs as a delivery system for the human four-repeat tau isoform lacking N-terminal sequences (4R0N) and enhanced green fluorescent protein (EGFP) into Neuro-2a cells. EV-mediated transfection efficiency was compared with conventional methods, including lentiviral and chemical (lipofectamine and polyethyleneimine, PEI) approaches. Response surface methodology (RSM) was used to optimize EV-mediated delivery parameters.

EVs successfully delivered large plasmid DNA into Neuro-2a cells, resulting in detectable tau and EGFP expression. Optimization via RSM further improved gene delivery efficiency and reproducibility compared to unoptimized EV preparations and conventional transfection methods.

These findings demonstrate that EVs can serve as a robust and biocompatible platform for tau gene delivery, providing a promising alternative to traditional transfection strategies for generating physiologically relevant tauopathy models.

## Linked entities

- **Genes:** MAPT (microtubule associated protein tau) [NCBI Gene 4137]
- **Proteins:** MAPT (microtubule associated protein tau)
- **Chemicals:** lipofectamine (PubChem CID 100984821), PEI (PubChem CID 9033)
- **Diseases:** Alzheimer’s disease (MONDO:0004975), tauopathy (MONDO:0005574)

## Full-text entities

- **Diseases:** Alzheimer's disease (MESH:D000544), toxicity (MESH:D064420), Tauopathy (MESH:D024801)
- **Chemicals:** PEI (-), lipofectamine (MESH:C086724)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** Neuro-2a — Mus musculus (Mouse), Mouse neuroblastoma, Cancer cell line (CVCL_0470)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12587183/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12587183/full.md

## References

76 references — full list in the complete paper: https://tomesphere.com/paper/PMC12587183/full.md

---
Source: https://tomesphere.com/paper/PMC12587183